CD200, also known as OX-2 membrane glycoprotein, is a type-1 membrane glycoprotein. A member of the immunoglobulin superfamily, CD200 contains two immunoglobulin domains. Low expression of CD200 has been linked to multiple cancers, such as leukemia and lymphoma. Interestingly, over-expression of CD200 is also linked to poor prognosis in certain cancers, such as cutaneous SCC. RCC and ovarian tumors can express CD200 to suppress anti-tumor responses by the immune system. However, some studies indicate CD200 expression may inhibit metastasis; CD200 expression on local blood vessels suppresses diapedesis, and animal experiments suggest CD200 expression in lung tumors inhibits metastasis.